Opioid-dependence treatment in the era of recovery: insights from a UK survey of physicians, patients and out-of-treatment opioid users

References

• Alho, H., Sinclair, D., Vuori, E., & Holopainen, A. (2007). Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug & Alcohol Dependence, 88, 75–78
   PubMed Web of Science ®Google Scholar
• Auriacombe, M., Fatseas, M., Dubernet, J., Daulouede, J. P., & Tignol, J. (2004). French field experience with buprenorphine. American Journal of Addiction, 13, S17–S28
   PubMed Web of Science ®Google Scholar
• Bacha, J., Reast, S., & Pearlstone, A. (2010). Treatment practices and perceived challenges for European physicians treating opioid dependence. Heroin Addiction & Related Clinical Problems, 12, 9–19
   Web of Science ®Google Scholar
• Bao, Y. P., Liu, Z. M., Epstein, D. H., Du, C., Shi, J., & Lu, L. (2009). A meta-analysis of retention in methadone maintenance by dose and dosing strategy. American Journal of Drug & Alcohol Abuse, 35, 28–33
   PubMed Web of Science ®Google Scholar
• Bart, G. (2012). Maintenance medication for opiate addiction: The foundation of recovery. Journal of Addictive Diseases, 31, 207–225
   PubMed Web of Science ®Google Scholar
• Bell, J. (2007). The role of supervision of dosing in opioid maintenance treatment. Available at: http://www.who.int/substance_abuse/activities/supervision_dosing.pdf [last accessed 2 Jan 2014]
   Google Scholar
• Benyamina, A., & Stöver, H. (2012). Barriers to treatment access and informed patient choice in the treatment of opioid dependence in Europe. Heroin Addiction & Related Clinical Problems, 14, 65–80
   Web of Science ®Google Scholar
• Best, D., Rome, A., Hanning, K. A., White, W., Gossop, M., Taylor, A., & Perkins, A. (2010). Research for recovery: A review of the drugs evidence base. Scottish Government Social Research. Available at: http://www.scotland.gov.uk/Resource/Doc/321958/0103435.pdf [last accessed 2 Jan 2014]
   Google Scholar
• Caplehorn, J. R. (1994). A comparison of abstinence-oriented and indefinite methadone maintenance treatment. International Journal of Addiction, 29, 1361–1375
   PubMedGoogle Scholar
• Clausen, T., Anchersen, K., & Waal, H. (2008). Mortality prior to, during and after opioid maintenance treatment (OMT): A national prospective cross-registry study. Drug & Alcohol Dependence, 94, 151–157
   PubMed Web of Science ®Google Scholar
• Connock, M., Juarez-Garcia, A., Jowett, S., Frew, E., Liu, Z., Taylor, R. J., Fry-Smith, A., Day, E., Lintzeris, N., Roberts, T., Burls, A., & Taylor, R. S. (2007). Methadone and buprenorphine for the management of opioid dependence: A systematic review and economic evaluation. Health Technology Assessment, 11, 1–171, iii–iv
   PubMed Web of Science ®Google Scholar
• Dale-Perera, A., Goulão, J., & Stöver, H. (2012). Quality of care provided to patients receiving opioid maintenance treatment in Europe: Results from the EQUATOR. Heroin Addiction & Related Clinical Problems, 14, 23–38
   Web of Science ®Google Scholar
• Degenhardt, L., Randall, D., Hall, W., Law, M., Butler, T., & Burns, L. (2009). Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: Risk factors and lives saved. Drug & Alcohol Dependence, 105, 9–15
   PubMed Web of Science ®Google Scholar
• Department of Health, England. (2011). Public Health England's operating model factsheets. Available at: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_131882 [last accessed 2 Jan 2014]
   Google Scholar
• Department of Health (England) and the Devolved Administrations. (2007). Drug misuse and dependence: UK guidelines on clinical management. London: Department of Health (England), the Scottish Government, Welsh Assembly Government and Northern Ireland Executive. Available at: http://www.nta.nhs.uk/uploads/clinical_guidelines_2007.pdf [last accessed 2 Jan 2014]
   Google Scholar
• Drummond, D. C., & Perryman, K. (2007). Psychosocial interventions in pharmacotherapy of opioid dependence: A literature review. Available at: http://www.who.int/substance_abuse/activities/psychosocial_interventions.pdf [last accessed 2 Jan 2014]
   Google Scholar
• Fareed, A., Vayalapalli, S., Casarella, J., & Drexler, K. (2012). Effect of buprenorphine dose on treatment outcome. Journal of Addictive Diseases, 31, 8–18
   PubMed Web of Science ®Google Scholar
• Fischer, G., Nava, F., & Stöver, H. (2012). Outcomes of opioid-dependence treatment across Europe: Identifying opportunities for improvement. Heroin Addiction & Related Clinical Problems, 14, 39–50
   Google Scholar
• Fudala, P. J., Bridge, T. P., Herbert, S., Williford, W. O., Chiang, C. N., Jones, K., Collins, J., Raisch, D., Casadonte, P., Goldsmith, R. J., Ling, W., Malkerneker, U., McNicholas, L., Renner, J., Stine, S., & Tusel, D.; Buprenorphine/Naloxone Collaborative Study Group (2003). Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. New England Journal of Medicine, 349, 949–958
   PubMed Web of Science ®Google Scholar
• Gerra, G., Saenz, E., Busse, A., Maremmani, I., Ciccocioppo, R., Zaimovic, A., Gerra, M. L., Amore, M., Manfredini, M., Donnini, C., & Somaini, L. (2011). Supervised daily consumption, contingent take-home incentive and non-contingent take-home in methadone maintenance. Progress in Neuropsychopharmacol & Biological Psychiatry, 35, 483–489
   PubMed Web of Science ®Google Scholar
• Gordon, L., Tinsley, L., Godfrey, C., Parrott, S. (2006). The economic and social costs of Class A drug use in England and Wales, 2003/04; In: Home Office, Measuring different aspects of problem drug use: methodological developments. Available at: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/116642/hoor1606.pdf [last accessed 2 Jan 2014]
   Google Scholar
• Gossop, M., Marsden, J., Stewart, D., & Treacy, S. (2001). Outcomes after methadone maintenance and methadone reduction treatments: Two-year follow-up results from the National Treatment Outcome Research Study. Drug & Alcohol Dependence, 62, 255–264
   PubMed Web of Science ®Google Scholar
• Goulão, J., & Stöver, H. (2012). The profile of patients, out-of-treatment users and treating physicians involved in opioid maintenance treatment in Europe. Heroin Addiction & Related Clinical Problems, 14, 7–22
   Web of Science ®Google Scholar
• Gruber, V. A., Delucchi, K. L., Kielstein, A., & Batki, S. L. (2008). A randomized trial of 6-month methadone maintenance with standard or minimal counseling versus 21-day methadone detoxification. Drug & Alcohol Dependence, 94, 199–206
   PubMed Web of Science ®Google Scholar
• Gunderson, E. W., Fiellin, D. A., Levin, F. R., Sullivan, L. E., & Kleber, H. D. (2006). Evaluation of a combined online and in person training in the use of buprenorphine. Substances Abuse, 27, 39–45
   PubMedGoogle Scholar
• HM Government. (2010). Drug strategy 2010: Reducing demand, restricting supply, building recovery: Supporting people to live a drug free life. Department of Health and Home Office. Available at: https://www.gov.uk/government/policies/reducing-drugs-misuse-and-dependence [last accessed 2 Jan 2014]
   Google Scholar
• Kamien, J. B., Branstetter, S. A., & Amass, L. (2008). Buprenorphine-naloxone versus methadone maintenance therapy: A randomised double-blind trial with opioid-dependent patients. Heroin Addiction & Related Clinical Problems, 10, 5–18
   Web of Science ®Google Scholar
• Lind, B., Chen, S., Weatherburn, D., & Mattick, R. (2005). The effectiveness of methadone maintenance in controlling crime. British Journal of Criminology, 45, 201–211
   Web of Science ®Google Scholar
• Maremmani, I., & Gerra, G. (2010). Buprenorphine-based regimens and methadone for the medical management of opioid dependence: Selecting the appropriate drug for treatment. American Journal of Addiction, 19, 557–568
   PubMed Web of Science ®Google Scholar
• Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2009). Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Systematic Reviews, 2009, CD002209
   PubMedGoogle Scholar
• Mattick, R. P., Kimber, J., Breen, C., & Davoli, M. (2008). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Systematic Reviews, 2008, CD002207
   Google Scholar
• National Institute for Health and Care Excellence. (2007). Guidance: Methadone and buprenorphine for the management of opioid dependence. Available at: http://www.nice.org.uk/nicemedia/pdf/TA114Niceguidance.pdf [last accessed 2 Jan 2014]
   Google Scholar
• National Treatment Agency for Substance Misuse. (2012). Medications in recovery: Re-orientating drug dependence treatment. National Health System. Available at: http://www.nta.nhs.uk/uploads/medications-in-recovery-main-report3.pdf [last accessed 2 Jan 2014]
   Google Scholar
• Orman, J. S., & Keating, G. M. (2009). Buprenorphine/naloxone: A review of its use in the treatment of opioid dependence. Drugs, 69, 577–607
   PubMed Web of Science ®Google Scholar
• Paraherakis, A., Charney, D. A., Palacios-Boix, J., & Gill, K. (2000). An abstinence-oriented program for substance use disorders: Poorer outcome associated with opiate dependence. Canadian Journal of Psychiatry, 45, 927–931
   PubMed Web of Science ®Google Scholar
• Scottish Government. (2008). The road to recovery: a new approach to tackling Scotland's drug problem. Available at: http://www.scotland.gov.uk/Publications/2008/05/22161610/0 [last accessed 2 Jan 2014]
   Google Scholar
• Simojoki, K., & Alho, H. (2013). A five-year follow-up of buprenorphine abuse potential. Journal of Alcoholism & Drug Dependence, 1, 1–6
   Google Scholar
• Sorensen, J. L., & Copeland, A. L. (2000). Drug abuse treatment as an HIV prevention strategy: A review. Drug & Alcohol Dependence, 59, 17–31
   PubMed Web of Science ®Google Scholar
• Stöver, H. (2012). Assessing the current state of public-health-related outcomes in opioid dependence across Europe: Data from the EQUATOR analysis. Heroin Addiction & Related Clinical Problems, 14, 51–64
   Web of Science ®Google Scholar
• Stöver, H. (2011). Barriers to opioid substitution treatment access, entry and retention: A survey of opioid users, patients in treatment, and treating and non-treating physicians. European Addiction Research, 17, 44–54
   PubMed Web of Science ®Google Scholar
• Taylor, M., & Lewis, L. (2011). An economic analysis of the impact of crime and hospitalisation associated with different interventions for opioid abuse in the United Kingdom. Presented at the ISPOR 14th Annual European Congress. (Abstract PMH27)
   Google Scholar
• Walsh, S. L., Preston, K. L., Stitzer, M. L., Cone, E. J., & Bigelow, G. E. (1994). Clinical pharmacology of buprenorphine: Ceiling effects at high doses. Clinical Pharmacology & Therapeutics, 55, 569–580
   PubMed Web of Science ®Google Scholar
• Welsh Assembly Government. (2008). Working together to reduce harm the substance misuse strategy for Wales 2008–2018. Available at: www.wales.gov.uk/topics/housingandcommunity/safety/publications/strategy0818/?lang=en [last accessed 2 Jan 2014]
   Google Scholar
• Winstock, A. R., Lea, T., & Sheridan, J. (2008). Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia. International Journal of Drug Policy, 19, 450–458
   PubMed Web of Science ®Google Scholar
• World Health Organization. (2004). WHO/UNODC/UNAIDS position paper: Substitution maintenance therapy in the management of opioid dependence and HIV/AIDS prevention. Available at: www.who.int/substance_abuse/publications/treatment/en/index.html [last accessed 2 Jan 2014]
   Google Scholar
• World Health Organization. (2009). Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Available at: www.who.int/substance_abuse/publications/treatment/en/index.html [last accessed 2 Jan 2014]
   Google Scholar